Placental graft trial aims to heal bedsores faster
NCT ID NCT06918548
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a wound covering made from donated human placenta, called NeoThelium FT, helps heal chronic pressure ulcers (bedsores) better than standard care alone. About 148 adults with pressure ulcers on the pelvis or legs will be randomly assigned to receive either the graft plus standard care or standard care only. The main goal is to see if more wounds close completely with the graft.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- NeoThelium FT (a dehydrated wound covering made from donated human placental tissue)
- What this could lead to
- If it works, this could provide a new treatment option to help heal chronic pressure ulcers faster and more completely.
- What could go wrong
- This is an early-stage trial with no phase designation, so results are uncertain. The treatment may not heal wounds better than standard care alone, and there is a risk of infection or rejection of the graft.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 148 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or Female, 18 years of age or older 2. Subject has a medical diagnosis of Pressure Injury/Ulcer located on the pelvis or lower extremity 3. Subject has a Pressure Injury/Ulcer present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC 4. Subject has a Pressure Injury/Ulcer with a historical wound measurement showing less than 50% healing within 30 days prior to randomization 5. Subject has a Pressure Injury/Ulcer with screening wound measurement showing less than 25% healing within 14 days prior to randomization 6. Subject has a Pressure Injury/Ulcer Stage 2, 3, and 4 without infection or clinically visible exposed bone 7. Index ulcer is a minimum of 1cm2 and a maximum of 25cm2 at first treatment visit 8. Index ulcer has a maximum depth of 1cm at first screening visit 9. Pressure Injury/Ulcer is treated with offloading therapy while standing, sitting and lying down (if applicable to wound location) for 14 days prior to randomization 10. Adequate circulation of ulcer demonstrated by an ABI of \>0.7 and \<1.3, or TBI of \>0.6 within 30 days prior to randomization 11. Index ulcer is free of infection prior to randomization and during screening phase. 12. Index ulcer is free of necrotic debris prior to \[insert product/device\] application 13. Female subjects of childbearing potential having a negative pregnancy test prior to randomization 14. Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization. 15. Having a Mini Nutritional Assessment Score of 12 or higher indicated a normal nutritional status 16. Subject is able and willing to follow the protocol requirements 17. Subject had signed informed consent 18. If 2 or more ulcers are present, the ulcers must be separated by at least 1 cm Exclusion Criteria: 1. Subject has a known life expectancy of \<1 year 2. Subject is unable to comply with protocol treatment 3. Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing 4. Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound 5. Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator 6. Known contraindications to tissue-engineered allograft 7. Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing 8. Wound reduces in area by ≥25% after 14 days of SOC prior to randomization 9. Subject is pregnant or breastfeeding 10. Subject with history of immunosuppressant treatment (systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the ulcer surface for \>2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study 11. Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization 12. Pressure Injury/Ulcer of Stage 4 grade with active osteomyelitis or exposed visible bone 13. Wound depth with visible exposed bone 14. HBOT within 14 days prior to randomization 15. Revascularization surgery on the index ulcer leg within 30 days of screening phase 16. Index ulcer suspicious of neoplasm in the opinion of the principal investigator
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pressure injury are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI-Crafted care plan aims to stop a common ICU harm
- Can artificial intelligence stop bedsores before they start?
- A simpler air mattress may prevent bedsores just as well — trial puts it to the test
- Blood gas clues could predict bedsores in intensive care
- Smartphone app aims to ease bed sore care for homebound patients
- Ear injury diagnosis showdown: which grading system wins?